Gynecomastia, Male Breast Enlargement
Conditions
Keywords
ultrasound, fat
Brief summary
Male volunteers who suffer from Pseudogynecomastia and seek noninvasive breast fat reduction will be enrolled into two arms to receive three biweekly UltraShape treatments.
Detailed description
Up to 40 adult male volunteers, who suffer from Pseudogynecomastia, and seek noninvasive breast fat reduction will be enrolled at up to three investigational sites. Eligible subject will be divided into one of the two treatment arms: Arm 1: Subjects will be treated on one side of the breast, while the opposite side will serve as control - Up to 20 subjects; Arm 2: Subjects will be treated on both sides of the breast - Up to 20 subjects. Subjects will receive 3 bi-weekly treatments (at 2-week intervals) with the UltraShape device. Subjects will return for 3 follow-up visits post last treatment (Tx.3): four weeks follow-up (4wk FU), eight weeks follow-up (8wk FU) and 12 weeks follow-up (12wk FU) for total expected study duration of 16 weeks.
Interventions
DEVICEUltraShape focused ultrasound device
3 biweekly focused ultrasound treatments to the male chest with UltraShape.
Sponsors
Syneron Medical
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. Signed informed consent to participate in the study 2. Male subjects, 18 -70 years of age at the time of enrollment 3. BMI interval: BMI ≥ 22 and ≤30 (normal to overweight, but not obese) 4. Fat thickness of at least 1.5 cm in the treated area (breast) as measured by calibrated caliper. 5. Subject has clearly visible, palpable, excess fatty tissue in their breast area, and minimal fibrous tissue. 6. Subject agrees to maintain their weight (i.e., within 3% weight change) by not making any major changes in their diet or lifestyle during the course of the study. 7. General good health confirmed by medical history and skin examination of the treated area. 8. Willing to follow the treatment and follow-up schedule and post-treatment care instructions. 9. Willing to have photographs and images taken of the treated areas to be used, de-identified in evaluations, publications and presentations.
Exclusion criteria
1. History of hypertension, ischemic heart disease, valvular heart disease, congestive heart failure, pacemaker/defibrillator. 2. Known hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue disease. 3. Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions. 4. Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator. 5. Having a permanent implant in the treated area, such as metal plates or an injected chemical substance such as silicone. 6. Having undergone any other surgery in the treated areas within 12 months of treatment or during the study, including liposuction. 7. Previous body contouring procedures in the treatment area within 12 months. 8. History of skin disease in the treatment area, known tendency to form keloids or poor wound healing. 9. Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course. 10. Skin lesions in the treatment area other than simple nevi on physical examination (e.g., atypical nevus, tattoo, abrasions) including depressed scars in the treatment area. 11. Very poor skin quality (i.e., severe laxity) according to the investigator decision. 12. Obesity (BMI \>30). 13. Unstable weight within the last 6 months (i.e., 3% weight change in the prior six months). 14. Inability to comply with circumference measurement procedure (e.g., inability to hold breath for the required duration). 15. Fat thickness lower than 2.5 cm after strapping at the treated area. 16. Participation in another clinical study involving same anatomical areas within the last 6 months (or 30 days in case different anatomical areas were treated in previous trial/s). 17. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study. 18. Personal history of previous breast malignancy. 19. Subject is taking any medication which could cause abnormal breast enlargement - including but not limited to: digoxin, furosemide, gonadotropins, clomiphene, phenytoin, and exogenous testosterone, ketoconazole, metronidazole, alkylating agents, cisplatin, spironolactone, cimetidine, flutamide, finasteride, etomidate, isonicotinic acid hydrazide, methyldopa, busulfan, tricyclic antidepressants, diazepam, penicillamine, omeprazole, phenothiazines, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors. 20. Subject has history of the following medical conditions: Klinefelter syndrome, Congenital anorchia, Testicular trauma, Testicular torsion, Viral orchitis, Kallmann syndrome , Pituitary tumors, Malignancies that increase the serum level of hCG (eg, large cell lung cancer, gastric carcinoma, renal cell carcinoma, hepatoma), Renal failure, Hyperthyroidism, Malnutrition, Androgen insensitivity syndrome, Five-alpha-reductase deficiency syndrome.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reduction in breast fat thickness after 3 treatments compared to baseline | 12 weeks after 3rd treatment (16 weeks) | Average reduction in breast fat thickness after 3 treatments compared to baseline, as measured by ultrasound imaging |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Reduction in breast fat thickness on treated side compared to control side | 12 weeks after 3rd treatment (16 weeks) | Average reduction in breast fat thickness on treated side compared to control side, as measured by ultrasound imaging (Arm 1 only) |
| Reduction in breast/chest circumference after 3 treatments compared to baseline | At 4-week, 8-week and 12-week follow-ups | Average reduction in breast/chest circumference after 3 treatments compared to baseline, as measured by measuring tape (Arm 2 only) |
| Reduction in breast fat thickness compared to baseline | At 4-week, 8-week and 12-week follow-ups | Average reduction in breast fat thickness compared to baseline, as measured by skin caliper |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with adverse events | through study duration up to 1 year | The number of adverse events, severity, intervention and outcome, as reported on adverse event forms |
Outcome results
None listed